Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo

Perspectives on SANCUSO® (granisetron transdermal system)

How to use SANCUSO

Play Video

An oncology nurse walks through the simple steps to apply the SANCUSO patch for patients.

Play Video

An oncologist’s perspective

Play Video

Medical oncologist Allyson Ocean, MD, discusses preventing CINV in mechanically compromised patients.

Play Video

Identifying appropriate patients

Play Video

Medical oncology nurse Fran Necci discusses recognizing patients who may be appropriate for SANCUSO.

Play Video

Request a sample

You may have patients with chemotherapy-induced nausea and vomiting (CINV) who are appropriate for SANCUSO. Request a sample at no cost to see if SANCUSO is the right option for your patients.

Request Sample

Connect to stay informed

You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.

Stay Informed
Indication and Important Safety Information

Indication

SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.

Important Safety Information

Contraindications

SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.

Warnings and Precautions

Adverse Reactions

The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).

To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-SANCUSO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full Prescribing Information for SANCUSO.